Search results for "bone"

showing 10 items of 2629 documents

The influence of ossein-hydroxyapatite compound ('Ossopan') on the healing of a bone defect.

1986

A study was undertaken in 60 adult rabbits in order to determine the effects of ossein-hydroxyapatite compound on bone healing. Standardized bony defects were produced in the distal femoral epiphyses, after which animals were randomized into four equal groups. An untreated group served as a control. One group received ossein-hydroxyapatite compound, 830 mg per day, a second group received bone mineral (ossein-hydroxyapatite compound reduced to ash, to remove organic constituents), 510 mg per day, and a third group received calcium carbonate, 650 mg per day. A series of fluorescent vital markers was administered to the animals from the 7th to the 32nd day after production of the defect. A th…

medicine.medical_specialtyDentistryBone healingMineralization (biology)Bone remodelingCalcium Carbonatechemistry.chemical_compoundFractures BoneInternal medicinemedicineAnimalsHydroxyapatitesFemurBone regenerationBone mineralWound Healingbusiness.industryGeneral MedicineCalcium carbonateEndocrinologyDurapatitechemistryMicroscopy FluorescenceDietary mineralDrug EvaluationFemaleHydroxyapatitesRabbitsbusinessCurrent medical research and opinion
researchProduct

Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover

2005

We studied clinical performance of serum TRACP 5b and other bone turnover markers, including S-CTX, U-DPD, S-PINP, S-BALP, and S-OC, for monitoring alendronate treatment. TRACP 5b had higher clinical sensitivity, area under the ROC curve, and signal-to-noise ratio than the other markers. INTRODUCTION: The purpose of this study was to compare the clinical performance of serum TRACP 5b (S-TRACP5b) with that of other markers of bone turnover in the monitoring of alendronate treatment. MATERIALS AND METHODS: This double-blinded study included 148 healthy postmenopausal women that were randomly assigned into two groups: one receiving 5 mg alendronate daily (n=75) and the other receiving placebo …

medicine.medical_specialtyDeoxypyridinolineEndocrinology Diabetes and MetabolismAcid PhosphataseUrologyPlaceboBone resorptionBone remodelingchemistry.chemical_compoundDouble-Blind MethodOsteogenesisInternal medicinemedicineVitamin D and neurologyHumansOrthopedics and Sports MedicineVitamin DAlendronateBone Density Conservation AgentsReceiver operating characteristicbiologyTartrate-Resistant Acid Phosphatasebusiness.industryAlendronic acidMiddle AgedIsoenzymesPostmenopauseEndocrinologychemistryOsteocalcinbiology.proteinCalciumFemaleDrug MonitoringbusinessBiomarkersmedicine.drugJournal of Bone and Mineral Research
researchProduct

Diffusion-weighted MRI of cholesteatomas of the petrous bone

2002

Purpose To investigate if primary cholesteatomas of the petrous bone show high signal in diffusion-weighted imaging (DWI). Materials and methods In this blinded study, we compared 15 patients with clinically certain cases and later surgically proven cholesteatomas vs. 12 patients with clinically acute otitis of the middle ear and 20 volunteers without petrous bone disease. Two blinded readers without knowledge of the clinical data decided in consensus agreement whether there was a pathologic signal increase in the petrous bone in an anisotropic single-shot echo-planar imaging (EPI) DWI sequence, an artifact, or no signal increase. Results Thirteen of 15 patients with cholesteatomas showed b…

medicine.medical_specialtyEar MiddlePetrous boneotorhinolaryngologic diseasesmedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesCholesteatomaProspective cohort studyNeuroradiologymedicine.diagnostic_testEcho-Planar Imagingbusiness.industryCholesteatomaMagnetic resonance imagingmedicine.diseaseMagnetic Resonance ImagingOtitis MediaOtitismedicine.anatomical_structureMiddle earRadiologymedicine.symptomArtifactsbusinessPetrous BoneDiffusion MRIJournal of Magnetic Resonance Imaging
researchProduct

Tartrate-Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone Resorption

2000

Human serum contains two forms of tartrate-resistant acid phosphatase (TRAP), 5a and 5b. Of these, 5a contains sialic acid and 5b does not. We show here that antigenic properties and pH optimum of TRAP purified from human osteoclasts are identical to those of serum TRAP 5b and completely different from those of serum TRAP 5a, suggesting that 5b would be derived from osteoclasts and 5a from some other source. We developed a novel immunoassay specific for 5b using a monoclonal antibody O1A as capture antibody. O1A did not bind acid phosphatase derived from platelets and erythrocytes. Western analysis showed that O1A was specific for TRAP in both human bone and serum. We measured bound TRAP ac…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismAcid PhosphataseNeuraminidaseBone resorptionPlaceboschemistry.chemical_compoundDouble-Blind MethodReference ValuesOsteoclastInternal medicineEnzyme StabilitymedicineHumansOrthopedics and Sports MedicineBone ResorptionIncubationTartrate-resistant acid phosphataseEstradiolmedicine.diagnostic_testbiologyTartrate-Resistant Acid PhosphataseEstrogen Replacement TherapyAcid phosphataseAntibodies MonoclonalMiddle AgedSialic acidResorptionIsoenzymesPostmenopauseEndocrinologymedicine.anatomical_structurechemistryImmunoassaybiology.proteinFemaleNorethindroneBiomarkersJournal of Bone and Mineral Research
researchProduct

Effect of β-cryptoxanthin plus phytosterols on cardiovascular risk and bone turnover markers in post-menopausal women: a randomized crossover trial.

2014

Abstract Background and aim Post-menopausal women are at higher risk of cardiovascular disease and bone demineralization. Phytosterols (PS) may be used for hypercholesterolemia in some groups and β-cryptoxanthin (β-Cx) displays a unique anabolic effect on bone. Our aim was to assess the changes in cardiovascular and bone turnover markers from the oral intake of β-Cx and PS in post-menopausal women. Methods and results A randomized, double-blind, crossover study with β-Cx (0.75 mg/day) and PS (1.5 g/day), single and combined, was performed in 38 postmenopausal women. Diet was supplemented with 1 × 250 mL milk-based fruit drink/day for 4 weeks with a wash-out period of 4-weeks in between. Ser…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismCampesterolOsteoporosisHypercholesterolemiaMedicine (miscellaneous)Parathyroid hormoneAdministration OralGastroenterologyBone and BonesBone remodelingchemistry.chemical_compoundDouble-Blind MethodRisk FactorsInternal medicineStatistical significancemedicineHumansCryptoxanthinsTriglyceridesAgedNutrition and DieteticsCross-Over StudiesDose-Response Relationship Drugbusiness.industryCholesterol HDLPhytosterolsCholesterol LDLMiddle Agedmedicine.diseaseCrossover studySitosterolsHealthy VolunteersClinical trialPostmenopauseEndocrinologyCholesterolTreatment OutcomechemistrySelective estrogen receptor modulatorCardiovascular DiseasesDietary SupplementsFemaleCardiology and Cardiovascular MedicinebusinessNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women

2006

To investigate the effects of a low transdermal estradiol dose on bone metabolism and to compare it with both the standard dose and absence of treatment.In this study performed in a third-level academic center, 66 healthy postmenopausal women underwent hormone therapy (HT) with patches containing estradiol at standard (0.050 mg/day, HT50, 33 women) or low dosage (0.025 mg/day, HT25, 33 women) and 70 women were without treatment (NT). The values (mean of three samples) of several bone biochemical parameters were compared between groups after adjusting for confounding factors. Bone mineral density (BMD) was assessed (by dual-energy X-ray absorptiometry) in the spine and hip in all cases, and …

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisCollagen Type IBone remodelingEndocrinologyBone DensityInternal medicinemedicineHumansOsteoporosis PostmenopausalTransdermalBone mineralAnalysis of VarianceDose-Response Relationship DrugEstradiolbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyMiddle AgedAlkaline Phosphatasemedicine.diseasePostmenopauseMenopauseDose–response relationshipEndocrinologyFemaleHormone therapyPeptidesDensitometrybusinessBiomarkersGynecological Endocrinology
researchProduct

A systematic review on regenerative alveolar graft materials in clinical trials

2021

Abstract Background Alveolar cleft grafting is a necessary procedure to restore bone defects. Randomized clinical trials (RCTs) are regarded as a golden standard for investigating the efficacy of treatments. Nevertheless, risk of bias (RoB) can still affect the validity of these trials. We aimed to conduct a systemic review of all control trials (CTs) using regenerative materials for alveolar cleft reconstructions to evaluate their RoB and perform a meta-analysis of new bone formation. Methods Cochrane Oral Health Group's Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (PubMed), EMBASE AND Google Scholar were searched up to October 2020. Thereafter, th…

medicine.medical_specialtyEvidence-based medicineMEDLINElaw.inventionIliumRandomized controlled triallawmedicineAdequacy of methodHumansTissue engineeringBone regenerationAutograftsIntention-to-treat analysisbusiness.industryEvidence-based medicineSDG 10 - Reduced InequalitiesRisk of biasJadad scaleSurgeryBone regenerationClinical trialCleft PalateMeta-analysisRegenerative medicine/dk/atira/pure/sustainabledevelopmentgoals/reduced_inequalitiesSurgeryCell transplantationbusinessAlveolar bone graftingJournal of Plastic, Reconstructive and Aesthetic Surgery
researchProduct

ENDOCRINOLOGY IN PREGNANCY: Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture

2015

Changes in bone density and bone markers suggest that pregnancy is associated with deterioration of bone mass in the mother. The metabolism of calcium resets to allow for the needs imposed by the building of the fetal skeleton. The fetus contributes to the process through the output of regulators from the placenta. Understanding of the whole process is limited, but some changes are unambiguous. There is an increase in the circulating levels of vitamin D, but its functional impact is unclear. Fetal parathyroid hormone (PTH) and PTH-related peptide (PTHrp) play an indirect role through support of a calcium gradient that creates hypercalcemia in the fetus. Placental GH, which increases up to t…

medicine.medical_specialtyFetusPregnancyBone densitybusiness.industryEndocrinology Diabetes and MetabolismOsteoporosisParathyroid hormoneGeneral Medicinemedicine.diseaseBone resorptionBone remodelingEndocrinologyEndocrinologyOsteoprotegerinInternal medicinemedicinebusinessEuropean Journal of Endocrinology
researchProduct

Ultrasonography utilization in forearm fractures at the emergency department

2019

medicine.medical_specialtyForearm injurymedicine.diagnostic_testbusiness.industryMEDLINEForearm InjuriesGeneral MedicineEmergency departmentUlna FracturesSurgeryForearmFractures BoneEmergency trauma Fluoroscopy Forearm fractures Ultrasonographymedicine.anatomical_structureForearmEmergency MedicineHumansMedicineFluoroscopyUltrasonographyChildEmergency Service HospitalbusinessUlna FracturesUltrasonographyThe American Journal of Emergency Medicine
researchProduct

Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study

2006

None of the available osteoporosis therapies have been shown to completely abolish the risk of fractures. In clinical practice, the outcome may be even poorer. In 880 patients prescribed with antiresorptives (alendronate, risedronate, and raloxifene) for >1 year, a fragility fracture was recorded in 8.9%/year of them. This incidence is considerably higher than that observed in randomized clinical trials, and it was significantly related to poor compliance and lack of supplementation with calcium and vitamin D. Introduction: Osteoporotic fracture is one of the most important public health concerns among the elderly. Currently available therapies have been shown to significantly decrease the …

medicine.medical_specialtyFracture riskEndocrinology Diabetes and MetabolismOsteoporosisIncidence; FRACTURETreatment resistancelaw.inventionCalcium and vitamin D intake Fracture risk Osteoporosis Treatment compliance Treatment resistancecalcium and vitamin d intake; fracture risk; osteoporosis; treatment compliance; treatment resistanceFractures BoneRandomized controlled trialRisk FactorslawInternal medicineCalcium and vitamin D intakemedicineVitamin D and neurologyHumansOrthopedics and Sports MedicineRaloxifeneVitamin DAgedRetrospective StudiesAlendronateBone Density Conservation Agentsbusiness.industryIncidenceIncidence (epidemiology)Etidronic AcidRetrospective cohort studyMiddle Agedmedicine.diseaseCalcium and vitamin D intake Fracture incidence Fracture risk Osteoporosis Treatment compliance Treatment resistanceFRACTUREFracture incidenceSurgeryItalyRaloxifene HydrochlorideRisedronic acidOsteoporosisFemaleObservational studyTreatment compliancebusinessRisedronic Acidmedicine.drug
researchProduct